ERAS - Erasca, Inc.

QQQ $ 478.80 $ -0.80 (-0.17 %)

DIA $ 391.21 $ 0.22 (0.06 %)

SPY $ 545.04 $ 0.21 (0.04 %)

TLT $ 93.14 $ -1.36 (-1.44 %)

GLD $ 212.60 $ -1.98 (-0.92 %)

Previous Close

$ 2.2

Open

$ 2.14

Bid

$ 2.20 x 1,000

Ask

$ 2.21 x 1,000

Day's Range

$ 2.03 - $ 2.23

52 Week Range

$ 1.51 - $ 2.97

Volume

2,829,831

Average Volume

Market Cap

314.42M

Beta (5Y Monthly)

$ 1.73

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-27-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-23-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-24-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-26-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Erasca Initiates SEACRAFT-2 Pivotal Phase ...
06/18/2024 12:05:36

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and h...

Goldman Sachs Maintains Buy on Erasca, Low...
05/28/2024 15:40:09

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $7 to $4.

elf-beauty-posts-upbeat-earnings-joins-nvidia-liveramp-holdings-borr-drilling-and-other-big-stocks-moving-higher-on-thursday

e.l.f. Beauty Posts Upbeat Earnings, Joins...
05/23/2024 14:26:28

15m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggressively-buying

$1.5M Bet On This Healthcare Stock? Check ...
05/23/2024 12:47:33

HC Wainwright & Co. Maintains Buy on Erasc...
05/20/2024 10:28:33

HC Wainwright & Co. analyst Andres Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from ...

dxc-technology-issues-weak-outlook-joins-take-two-interactive-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

DXC Technology Issues Weak Outlook, Joins ...
05/17/2024 09:34:01

Reported Earlier, Erasca Prices Underwritt...
05/17/2024 05:23:44

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable sec...

Reported Earlier, Erasca Entered Into Excl...
05/17/2024 05:19:50

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class prof...

Erasca Plans To Deprioritize ERAS-007, ERA...
05/16/2024 20:36:18

The Company will deprioritize the ERAS-007 program as the Company believes the clinical efficacy data from the HERKULES-3 clini...

Erasca Reveals Reduction In Workforce By ~...
05/16/2024 20:29:14

https://www.sec.gov/ix?doc=/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm

HC Wainwright & Co. Reiterates Buy on Eras...
05/09/2024 11:40:32

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

Erasca Q1 EPS $(0.23) Misses $(0.22) Estimate
05/08/2024 21:04:28

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4...

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
04/19/2024 12:08:38

Goldman Sachs Maintains Buy on Erasca, Rai...
04/02/2024 16:16:19

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.

HC Wainwright & Co. Reiterates Buy on Eras...
03/28/2024 10:13:44

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

Reported Earlier, Erasca Announced $45M Ov...
03/28/2024 05:43:13

Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, d...

Erasca Q4 EPS $(0.20) Beats $(0.21) Estimate
03/27/2024 20:05:24

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.7...

Capital One Initiates Coverage On Erasca w...
03/11/2024 14:00:21

Capital One analyst Naureen Quibria initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price ...

Erasca Announces Two Clinical Trial Collab...
02/14/2024 13:10:16

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initia...

B of A Securities Downgrades Erasca to Neu...
01/05/2024 14:13:58

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Neutral and lowers the price target fro...

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)

ERASErasca, Inc.

Nasdaq erasca.com

$ 2.20 $ 0.12 (5.77 %)

Wednesday, 26-Jun-2024 15:59:53 EDT